Thyroid Nodule: When to See a Doctor

How Common Are Thyroid Nodules?

Thyroid nodules are among the most frequently encountered endocrine findings in clinical practice. High-resolution ultrasound detects nodules in 19% to 68% of randomly selected adults, with higher rates in women, older individuals, and populations with iodine deficiency [1]. The vast majority of these nodules produce no symptoms and are discovered incidentally during imaging ordered for unrelated reasons, such as carotid Doppler studies, CT scans of the chest, or PET scans.

Palpable nodules are far less common, found in roughly 4% to 7% of the general population on physical exam [2]. The clinical significance of a thyroid nodule depends not on its mere existence but on whether it shows features associated with malignancy, compresses surrounding structures, or produces excess thyroid hormone. Only about 5% to 15% of thyroid nodules evaluated by fine-needle aspiration (FNA) turn out to be malignant [1]. That means the large majority of people with a thyroid nodule will never need surgery or cancer treatment. Still, distinguishing the benign majority from the malignant minority requires a systematic evaluation.

What Causes Thyroid Nodules?

The precise cause of any individual thyroid nodule is often unclear, but several well-characterized risk factors drive nodule formation. Iodine deficiency remains the leading cause of multinodular goiter worldwide, though it is uncommon in countries with salt iodization programs [3]. Hashimoto's thyroiditis, the most prevalent autoimmune thyroid disorder, can produce nodular changes that mimic discrete nodules on ultrasound [4].

Radiation exposure stands out as a strong risk factor. Individuals who received external beam radiation to the head, neck, or upper chest during childhood face a 5- to 10-fold increase in thyroid nodule and cancer risk, with a latency period of 5 to 30 years [5]. The 2015 American Thyroid Association (ATA) guidelines specifically flag a personal history of head or neck irradiation as an indication for a lower threshold for biopsy [1].

Other contributing factors include family history of thyroid cancer (especially medullary thyroid carcinoma or MEN2 syndrome), age over 60, female sex, and obesity. A 2017 meta-analysis in Thyroid (N=12,199) found that BMI ≥30 was associated with a 1.3-fold increased risk of thyroid nodules compared to normal-weight controls [6]. Genetic predisposition also plays a role: first-degree relatives of patients with differentiated thyroid cancer carry a 4- to 10-fold elevated risk [1].

Red Flags: Symptoms That Warrant Prompt Evaluation

Most thyroid nodules are asymptomatic. A nodule that you can feel or see in the mirror does not automatically signal danger, but certain clinical features should prompt an urgent visit.

Rapid growth. A nodule that enlarges noticeably over weeks rather than months raises suspicion for anaplastic thyroid carcinoma or thyroid lymphoma, both of which are aggressive [1]. Anaplastic carcinoma accounts for only 1% to 2% of thyroid cancers but carries a median survival of 5 months [7].

Voice changes. Persistent hoarseness lasting longer than two weeks, especially without an upper respiratory infection, may indicate vocal cord paralysis from recurrent laryngeal nerve involvement. The 2015 ATA guidelines recommend that "patients with a thyroid nodule and voice symptoms should undergo preoperative laryngeal examination" [1].

Compressive symptoms. Difficulty swallowing (dysphagia), a choking sensation when lying flat, or shortness of breath can occur when nodules grow large enough to compress the esophagus or trachea. Substernal extension of a goiter sometimes causes these symptoms even when the visible neck portion appears modest.

Fixed, hard mass. A nodule that does not move with swallowing or feels stony-hard on palpation is more concerning than a soft, mobile nodule. Fixation to surrounding tissues suggests possible extracapsular extension.

Cervical lymphadenopathy. Enlarged, firm lymph nodes in the lateral neck or central compartment alongside a thyroid nodule raise the pretest probability of papillary thyroid carcinoma, the most common thyroid malignancy [1].

If none of these features are present, a nodule discovered incidentally still deserves evaluation if it measures 1 cm or larger on imaging. Smaller nodules (under 1 cm) generally require follow-up only if suspicious ultrasound features are present or the patient has high-risk factors such as radiation history [1].

How Thyroid Nodules Are Diagnosed

The diagnostic workup of a thyroid nodule follows a well-defined algorithm endorsed by the ATA, the American Association of Clinical Endocrinologists (AACE), and the American College of Radiology (ACR).

Step 1: TSH measurement. A serum TSH level is the recommended first-line laboratory test [1]. If TSH is low (suppressed), the next step is a radionuclide thyroid scan (I-123 or technetium-99m pertechnetate) to determine whether the nodule is hyperfunctioning ("hot"). Hot nodules are almost never malignant and typically do not require biopsy [8]. If TSH is normal or elevated, the evaluation proceeds to ultrasound.

Step 2: Thyroid ultrasound. High-resolution ultrasound is the single most important imaging modality for thyroid nodule assessment. The ACR Thyroid Imaging, Reporting and Data Specification System (TI-RADS) assigns points based on five ultrasound categories: composition, echogenicity, shape, margin, and echogenic foci [9]. Each nodule receives a TI-RADS level (TR1 through TR5) that dictates whether FNA or follow-up imaging is recommended and at what size threshold. A TR5 nodule (highly suspicious) warrants FNA at ≥1 cm, while a TR3 nodule (mildly suspicious) warrants FNA at ≥2.5 cm [9].

Step 3: Fine-needle aspiration biopsy. Ultrasound-guided FNA is the gold standard for determining whether a thyroid nodule is benign or malignant. The Bethesda System for Reporting Thyroid Cytopathology classifies FNA results into six categories [10]:

• Bethesda I: Nondiagnostic (repeat FNA recommended)
• Bethesda II: Benign (risk of malignancy 0% to 3%)
• Bethesda III: Atypia of undetermined significance (risk 6% to 18%)
• Bethesda IV: Follicular neoplasm (risk 10% to 40%)
• Bethesda V: Suspicious for malignancy (risk 45% to 60%)
• Bethesda VI: Malignant (risk 94% to 99%)

For indeterminate results (Bethesda III and IV), molecular testing panels such as Afirma GSC or ThyroSeq v3 can refine the malignancy risk estimate and help patients avoid unnecessary diagnostic surgery. A 2019 study in JAMA Oncology (N=257) demonstrated that ThyroSeq v3 achieved a negative predictive value of 97% for Bethesda III nodules, allowing more than half of patients tested to avoid surgery [11].

Treatment Options by Nodule Type

Treatment depends entirely on the diagnosis. Benign nodules require no treatment in most cases, only periodic ultrasound monitoring at 12 to 24 months after the initial benign FNA result [1]. If a benign nodule causes compressive symptoms or cosmetic concern, options include thyroid hormone suppression therapy (now generally discouraged due to cardiac and bone side effects), radiofrequency ablation (RFA), ethanol ablation for cystic nodules, or surgical lobectomy [12].

Malignant nodules. The standard treatment for confirmed thyroid cancer is surgery, either lobectomy (for low-risk papillary microcarcinomas <1 cm) or total thyroidectomy for larger or higher-risk cancers [1]. Radioactive iodine (I-131) ablation is used postoperatively in intermediate- and high-risk differentiated thyroid cancers. The ATA risk stratification system categorizes patients as low, intermediate, or high risk based on tumor size, extrathyroidal extension, lymph node involvement, and histologic subtype [1].

Dr. Bryan Haugen, lead author of the 2015 ATA guidelines and professor of medicine at the University of Colorado, noted that "the goal of initial therapy is to remove the primary tumor, disease that has extended beyond the thyroid capsule, and involved cervical lymph nodes" [1]. For low-risk papillary thyroid cancers <4 cm confined to the thyroid, lobectomy alone may be sufficient, sparing patients lifelong full-dose levothyroxine replacement.

Active surveillance. For papillary microcarcinomas (<1 cm) without aggressive features, active surveillance with serial ultrasound has emerged as a viable alternative to immediate surgery. A prospective study from Kuma Hospital in Japan followed 1,235 patients with papillary microcarcinomas and found that only 8% showed tumor enlargement over 10 years, and none died of thyroid cancer during follow-up [13]. The 2015 ATA guidelines acknowledge active surveillance as an appropriate management strategy for "very low-risk tumors" in properly selected patients [1].

The Role of Thyroid Function Tests Beyond TSH

While TSH is the essential first test, additional labs may be warranted depending on clinical context. Thyroid peroxidase (TPO) antibodies help identify Hashimoto's thyroiditis when the ultrasound shows diffuse heterogeneity alongside nodules [4]. Serum calcitonin, though not universally recommended by the ATA as a screening test, can detect medullary thyroid carcinoma (MTC) at an earlier stage. The European Thyroid Association and AACE/AME guidelines do recommend routine calcitonin measurement in the initial workup of thyroid nodules [14].

A basal calcitonin level above 100 pg/mL is strongly suggestive of MTC, with a positive predictive value exceeding 90% [14]. MTC accounts for approximately 3% to 5% of all thyroid cancers but has a significantly worse prognosis than differentiated thyroid cancers when diagnosed at an advanced stage, with 10-year survival dropping from 95% in stage I to 40% in stage IV [15]. Early detection through calcitonin screening, paired with RET proto-oncogene testing, allows for prophylactic thyroidectomy in MEN2 kindreds before the cancer becomes clinically apparent.

Thyroglobulin levels are not useful for initial nodule evaluation but become a critical surveillance biomarker after thyroidectomy for differentiated thyroid cancer [1].

Radiation History and Special Populations

Certain populations require a modified approach. Children and adolescents with thyroid nodules have a higher malignancy rate (22% to 26%) compared to adults [16]. The ATA published separate pediatric guidelines in 2015 recommending FNA for any nodule ≥1 cm in a child, regardless of ultrasound appearance, given the higher pretest probability of cancer [16].

Pregnant women with thyroid nodules present a unique challenge. FNA can be performed safely during any trimester, but radionuclide scanning is contraindicated [1]. If a nodule is found to be malignant during pregnancy, surgery is safest during the second trimester if clinically indicated, though many low-risk cancers can be monitored until after delivery [1].

Patients with a history of childhood radiation exposure (therapeutic or environmental, such as the Chernobyl cohort) should undergo baseline thyroid ultrasound. A 2011 study in The Journal of Clinical Endocrinology & Metabolism found that thyroid cancer incidence among Chernobyl-exposed children was 5 to 10 times higher than in unexposed controls, with excess risk persisting for at least 20 years after exposure [17].

When You Can Safely Watch and Wait

Not every thyroid nodule demands immediate intervention. Clear criteria exist for safe observation. A nodule that is purely cystic (fluid-filled) on ultrasound is almost never malignant and typically needs only a single follow-up ultrasound [9]. Nodules classified as TR1 or TR2 on ACR TI-RADS do not require FNA at any size [9].

A Bethesda II (benign) FNA result carries a false-negative rate of approximately 1% to 3% [10]. The ATA recommends repeat ultrasound in 12 to 24 months after a benign FNA. If the nodule remains stable over two consecutive surveillance intervals, the monitoring interval can be extended or discontinued [1]. Growth alone (defined as a 20% increase in at least two dimensions with a minimum increase of 2 mm) does not automatically indicate malignancy but does warrant repeat FNA [1].

Patients with suppressed TSH and a corresponding "hot" nodule on scintigraphy can be reassured that the malignancy risk is extremely low (<1%), though they may need treatment for hyperthyroidism itself [8].